|Bid||107.61 x 1400|
|Ask||107.60 x 1100|
|Day's range||107.10 - 108.25|
|52-week range||79.11 - 121.53|
|Beta (5Y monthly)||0.79|
|PE ratio (TTM)||29.10|
|Earnings date||28 Oct 2021 - 01 Nov 2021|
|Forward dividend & yield||5.20 (4.83%)|
|Ex-dividend date||14 Oct 2021|
|1y target est||125.96|
AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq - active ulcerative colitis.
AbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government.
The market has written off these two high-quality stocks, but both could complement an income investor's portfolio.